Objective: To evaluate the clinical efficacy and safety of dupilumab in the treatment of pediatric atopic dermatitis (AD). Methods: A total of 36 patients who met the inclusion criteria were selected and treated with dupilumab for 16 weeks. The following assessment scales were collected: SCORing Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), Childhood Dermatitis Life Quality Index (CDLQI), Numerical Rating Scale (NRS) for pruritus and sleep, Atopic Dermatitis Control Tool (ADCT), and Patient-Oriented Eczema Measure (POEM). Statistical analysis was performed on the data, and adverse events were recorded. Results: At week 16 of treatment, 97 .06% (33/34), 70.59% (24/34), and 32.35% (11/34) of patients achieved EASI-50, EASI- 75, and EASI-90, respectively . The SCORAD score decreased from 62.35±14.30 to 25.59±10.74 (P